Literature DB >> 19426420

Complications of continuous renal replacement therapy.

Kevin W Finkel1, Amber S Podoll.   

Abstract

Continuous renal replacement therapy (CRRT) is commonly used in critically ill patients with acute kidney injury. Many studies show that compared with intermittent hemodialysis, continuous therapy has superior hemodynamic stability, metabolic clearance, and volume control. Despite these benefits, no survival advantage can be demonstrated with its use. Although study design explains much of this paradox, it is also quite plausible that the complications associated with CRRT negate its potential benefits in the critically ill patient. We summarize the common complications associated with the use of CRRT.

Entities:  

Mesh:

Year:  2009        PMID: 19426420     DOI: 10.1111/j.1525-139X.2008.00550.x

Source DB:  PubMed          Journal:  Semin Dial        ISSN: 0894-0959            Impact factor:   3.455


  19 in total

Review 1.  The dark side of high-intensity renal replacement therapy of acute kidney injury in critically ill patients.

Authors:  Helmut Schiffl
Journal:  Int Urol Nephrol       Date:  2010-04-10       Impact factor: 2.370

2.  Intensity of Renal Replacement Therapy and Duration of Mechanical Ventilation: Secondary Analysis of the Acute Renal Failure Trial Network Study.

Authors:  Shilpa Sharma; Yvelynne P Kelly; Paul M Palevsky; Sushrut S Waikar
Journal:  Chest       Date:  2020-05-26       Impact factor: 9.410

Review 3.  Continuous Renal Replacement Therapy: Who, When, Why, and How.

Authors:  Srijan Tandukar; Paul M Palevsky
Journal:  Chest       Date:  2018-09-25       Impact factor: 9.410

4.  Effects of Baseline Thrombocytopenia and Platelet Decrease Following Renal Replacement Therapy Initiation in Patients With Severe Acute Kidney Injury.

Authors:  Benjamin R Griffin; Anna Jovanovich; Zhiying You; Paul Palevsky; Sarah Faubel; Diana Jalal
Journal:  Crit Care Med       Date:  2019-04       Impact factor: 7.598

5.  Bullous Lesions After Use of a Commercial Therapeutic Hypothermia Temperature Management System: A Possible Burn Injury?

Authors:  Henry E Wang; James M Wells; Dana V Rizk
Journal:  Ther Hypothermia Temp Manag       Date:  2013-09       Impact factor: 1.286

6.  A bioinspired omniphobic surface coating on medical devices prevents thrombosis and biofouling.

Authors:  Daniel C Leslie; Anna Waterhouse; Julia B Berthet; Thomas M Valentin; Alexander L Watters; Abhishek Jain; Philseok Kim; Benjamin D Hatton; Arthur Nedder; Kathryn Donovan; Elana H Super; Caitlin Howell; Christopher P Johnson; Thy L Vu; Dana E Bolgen; Sami Rifai; Anne R Hansen; Michael Aizenberg; Michael Super; Joanna Aizenberg; Donald E Ingber
Journal:  Nat Biotechnol       Date:  2014-10-12       Impact factor: 54.908

7.  Management of metformin-associated lactic acidosis by continuous renal replacement therapy.

Authors:  Geoffray Keller; Martin Cour; Romain Hernu; Julien Illinger; Dominique Robert; Laurent Argaud
Journal:  PLoS One       Date:  2011-08-11       Impact factor: 3.240

8.  Complications of continuous renal replacement therapy in critically ill children: a prospective observational evaluation study.

Authors:  Maria J Santiago; Jesús López-Herce; Javier Urbano; María José Solana; Jimena del Castillo; Yolanda Ballestero; Marta Botrán; Jose María Bellón
Journal:  Crit Care       Date:  2009-11-23       Impact factor: 9.097

9.  Hemolysis During Pediatric Extracorporeal Membrane Oxygenation: Associations With Circuitry, Complications, and Mortality.

Authors:  Heidi J Dalton; Katherine Cashen; Ron W Reeder; Robert A Berg; Thomas P Shanley; Christopher J L Newth; Murray M Pollack; David Wessel; Joseph Carcillo; Rick Harrison; J Michael Dean; Kathleen L Meert
Journal:  Pediatr Crit Care Med       Date:  2018-11       Impact factor: 3.624

10.  Prolonged exposure to continuous renal replacement therapy in patients with acute kidney injury.

Authors:  Khaled Shawwa; Panagiotis Kompotiatis; Ankit Sakhuja; Paul McCarthy; Kianoush B Kashani
Journal:  J Nephrol       Date:  2021-06-23       Impact factor: 3.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.